The gammaherpesvirus variably known as Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus eight (HHV8) is the likely etiologic agent of two malignancies, Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), that occur in patients with AIDS. In the majority of cells of these two KSHV-associated tumors the virus remains in a latent state, but in a subpopulation of cells KSHV is activated into lytic cycle gene expression. The applicants have found that a number of KSHV genes that are homologues of cellular chemokines, cytokines and anti-apoptotic factors that likely play critical roles in virus biology are expressed during the lytic phase of viral gene expression both in KS biopsies and in cell lines derived from PEL. As a seminal clue to the mechanism of lytic cycle activation we have identified a KSHV immediate-early gene product termed KSHV/Rta, partially encoded in ORF50, that activates expression of lytic cycle genes including vIL6 in PEL cells. Their global objective is to understand the role of the ORF50 gene product in the switch between latency and lytic cycle gene expression both in B cells and in microvascular endothelial cells. The investigators will analyze the events downstream of KSHV/Rta expression to determine whether ORF50/Rta is competent to activate the entire viral lytic cycle program. Using ribozyme inhibition the applicants will learn whether ORF50 is essential for reactivation of the virus. They will study the mechanism of action of KSHV/Rta, learning whether it acts directly, by binding DNA in the promoters of downstream genes, or indirectly recognizing DNA via other proteins. They will explore whether it autostimulates its own expression. They will delineate the pathway leading to activation of ORF50 expression, ultimately learning whether this activation is accompanied by acquisition or loss of cellular proteins that bind to the promoter of the ORF50 gene. They will determine whether the KSHV/ORF50 product plays an activating role in de novo infection of hematopoietic and endothelial cells or only functions during lytic cycle reactivation. The proposed experiments employ a combination of biologic, molecular, genetic and biochemical approaches to study a central feature of the KSHV life cycle. The studies should provide insights into molecular pathogenesis of KSHV-associated disease and address fundamental questions about control of oncogenic herpesvirus gene expression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA070036-08
Application #
6633104
Study Section
Special Emphasis Panel (ZRG1-AARR-4 (01))
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1995-09-30
Project End
2005-05-31
Budget Start
2003-06-01
Budget End
2005-05-31
Support Year
8
Fiscal Year
2003
Total Cost
$355,902
Indirect Cost
Name
Yale University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Miller, George; El-Guindy, Ayman; Countryman, Jill et al. (2007) Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res 97:81-109
Chang, Pey-Jium; Shedd, Duane; Miller, George (2005) Two subclasses of Kaposi's sarcoma-associated herpesvirus lytic cycle promoters distinguished by open reading frame 50 mutant proteins that are deficient in binding to DNA. J Virol 79:8750-63
Chen, Lee-Wen; Chang, Pey-Jium; Delecluse, Henri-Jacques et al. (2005) Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J Virol 79:9635-50
Ye, Jianjiang; Shedd, Duane; Miller, George (2005) An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol 79:1397-408
Chang, Pey-Jium; Miller, George (2004) Autoregulation of DNA binding and protein stability of Kaposi's sarcoma-associated herpesvirus ORF50 protein. J Virol 78:10657-73
Dela Cruz, Charles S; Lee, Yoomi; Viswanathan, Srinivas R et al. (2004) N-linked glycosylation is required for optimal function of Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6. J Exp Med 199:503-14
Chang, Pey-Jium; Shedd, Duane; Gradoville, Lyn et al. (2002) Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J Virol 76:3168-78
Almuneef, M; Nimjee, S; Khoshnood, K et al. (2001) Prevalence of antibodies to human herpesvirus 8 (HHV-8) in Saudi Arabian patients with and without renal failure. Transplantation 71:1120-4
Gradoville, L; Gerlach, J; Grogan, E et al. (2000) Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol 74:6207-12
Cinquina, C C; Grogan, E; Sun, R et al. (2000) Dihydrofolate reductase from Kaposi's sarcoma-associated herpesvirus. Virology 268:201-17

Showing the most recent 10 out of 20 publications